NewsBabel NewsBabel

Global headlines in real time

1 Items
Active filters Topic: Glp-1 Clear all

Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings

Tmt Newswire
23 Sep 2026, 11:48 GMT GlobeNewswire

As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks

Download options
The Manila Times logo
Article Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Credit: GlobeNewswire